Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil targeted therapeutics in eosinophilic diseases

摘要

The present disclosure relates to protein and / or gene expression levels of dipeptidyl peptidase-4 (DPP4 / CD26) and periostin (POSTN) as peripheral biomarkers for eosinophilic diseases or disorders such as moderate to severe asthma. Regarding use. The level of DPP4 and / or POSTN above or below a given DPP4 or POSTN threshold level is, for example: To determine patient eligibility for treatment, (ii) specific treatment of eosinophilic disease or disorder with specific IL-5R antagonists should be initiated, discontinued or improved To determine whether (iii) eosinophilic disease or disorder is treatable with a specific IL-5R antagonist, or (iv) specific For predicting the outcome of treatment of an eosinophilic disease or disorder with a typical IL-5R antagonist. [Selection figure] None